AVANIR PHARMACEUTICALS for AVANIR PHARMACEUTICALS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Termination (this page) | Apr 6, 2018 | $80,000 | Replaced |
| 4th Quarter - Termination Amendment (No Activity) | Apr 9, 2018 | $60,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Alzheimer's research funding in the FY18 House and Senate Labor, HHS and Education Appropriations bills HR 3358 and S. 1771.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRYSTAL LYNN VANUCH | — |
Health Issues HCR
Long term care regulations; out of pocket costs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRYSTAL LYNN VANUCH | Head of Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.